Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Titel:
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Auteur:
Usmani, Saad Z Quach, Hang Mateos, Maria-Victoria Landgren, Ola Leleu, Xavier Siegel, David Weisel, Katja Gavriatopoulou, Maria Oriol, Albert Rabin, Neil Nooka, Ajay Qi, Ming Beksac, Meral Jakubowiak, Andrzej Ding, Bifeng Zahlten-Kumeli, Anita Yusuf, Akeem Dimopoulos, Meletios